Phase 1a/1b Trial of LTI-01 (Single Chain Urokinase, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions or Empyema
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2018
At a glance
- Drugs LTI 01 (Primary)
- Indications Acute lung injury; Idiopathic pulmonary fibrosis; Pleural effusion
- Focus Adverse reactions
- Sponsors Lung Therapeutics
- 20 Jun 2018 Status changed from recruiting to discontinued.
- 14 Mar 2017 According to a Lung Therapeutics media release, first patient has been enrolled and dosed in the study.
- 14 Mar 2017 Status changed from not yet recruiting to recruiting, as reported in a Lung Therapeutics media release.